|
 The drug, Vraylar, carries a boxed warning on increased risk of
death associated with its use in older people with dementia-related
psychosis, the FDA said on its website.
Vraylar was approved after showing efficacy in more than 2,700
adults, the company said.
The new drug will be the second antipsychotic to be sold by Allergan.
The company already sells Viibryd to treat major depressive disorder
in adults.
Allergan partnered Gedeon Richter Plc to develop Vraylar.
The company's shares were little changed at $301.02 in afternoon
trade on Thursday.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj
Kalluvila)
[to top of second column] |
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
